Analyst firms · Piper Sandler · ISRG

Piper Sandler ISRG price target and rating history

Intuitive Surgical Inc. (ISRG) · Health Care

Piper Sandler rates Intuitive Surgical Inc. (ISRG) Overweight with a $310 price target, as of its latest action on Jan 31, 2022. It has published 3 rating actions on ISRG since July 2021, including 1 upgrade and 0 downgrades. Across 7 firms with a ISRG price target in the last 12 months, the median target is $500.

Current rating
Overweight
Price target
$310
Median target, all firms
$500
Actions on ISRG
3

Piper Sandler price target on ISRG

$323$312$30020222023202420252026
Piper Sandler price target on ISRG, each point a stated target, July 2021 to January 2022. Targets before January 2022 (divided by 3) are adjusted for a stock split, going by the prior target Piper Sandler restated.

Every Piper Sandler rating on ISRG

How other firms rate ISRG

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Erste GroupBuyOct 21, 2026
BarclaysOverweight$485Oct 7, 2026
OppenheimerOutperform$500Aug 12, 2026
HSBCHold$391Jul 30, 2026
UBSBuy$500Jul 28, 2026
BMO Capital MarketsOutperform$518Jul 9, 2026
CitigroupBuy$590Mar 11, 2026
TD CowenBuy$660Jan 27, 2026

Questions about Piper Sandler and ISRG

What is Piper Sandler's price target for ISRG?
Piper Sandler's latest stated price target for Intuitive Surgical Inc. (ISRG) is $310, from its action on Jan 31, 2022.
What is Piper Sandler's rating on ISRG?
Piper Sandler rates ISRG Overweight, a bullish rating, as of Jan 31, 2022.
When did Piper Sandler last change its view on ISRG?
On Jan 31, 2022, Piper Sandler upgrades to Overweight from Neutral, price target $300 to $310.
How does Piper Sandler's ISRG target compare with other analysts?
Across 7 firms with a ISRG price target in the last 12 months, the median target is $500.

More ISRG rating histories

All Piper Sandler ratingsISRG news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.